TNFSF13 and systemic lupus erythematosus: Given the dual role of APRIL, anti-APRIL treatments may reduce pathogenic autoantibody production and disease flares, while preserving the regulatory function of Bregs. This could mitigate disease progression and improve clinical outcomes in SLE patients.